SG11201909478UA - Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication - Google Patents
Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replicationInfo
- Publication number
- SG11201909478UA SG11201909478UA SG11201909478UA SG11201909478UA SG 11201909478U A SG11201909478U A SG 11201909478UA SG 11201909478U A SG11201909478U A SG 11201909478UA SG 11201909478U A SG11201909478U A SG 11201909478UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- patient
- pharmaceutically acceptable
- biological sample
- pct
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
NN— L R Formula I, Formula III N 2 Formula II, or W O 20 18/ 200 425 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 01 November 2018 (01.11.2018) WIPO I PCT omit °nolo Hinz! onno oimIE (10) International Publication Number WO 2018/200425 Al (51) International Patent Classification: CO7D 519/00 (2006.01) A61K 31/519 (2006.01) A61P 31/16 (2006.01) (21) International Application Number: PCT/US2018/028986 (22) International Filing Date: 24 April 2018 (24.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/489,167 24 April 2017 (24.04.2017) US (71) Applicant: COCRYSTAL PHARMA, INC. [US/US]; 19805 North Creek Parkway, Bothell, WA 98011 (US). (72) Inventors: JACOBSON, Irina, C.; 2725 226th Place, NE, Sammamish, WA 98074 (US). FEESE, Michael, David; 3535 Meridian Ave N., Seattle, WA 98103 (US). LEE, Sam, Sk; 950 Brookmere St., Edmonds, WA 98020 (US). (74) Agent: DANEK, Shelley, C. et al.; Marshall, Gerstein & Borun LLP, 233-S. Wacker Drive, 6300 Willis Tower, Chicago, IL 60606-6357 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (54) Title: PYRROLOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF INFLUENZA VIRUS REPLICATION (57) : Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient a safe and effective amount of a compound represented by any of Formulas 1-111, or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a safe and effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762489167P | 2017-04-24 | 2017-04-24 | |
PCT/US2018/028986 WO2018200425A1 (en) | 2017-04-24 | 2018-04-24 | Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201909478UA true SG11201909478UA (en) | 2019-11-28 |
Family
ID=62117141
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201909478U SG11201909478UA (en) | 2017-04-24 | 2018-04-24 | Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication |
Country Status (19)
Country | Link |
---|---|
US (1) | US11014941B2 (en) |
EP (1) | EP3615545B1 (en) |
JP (1) | JP7165721B2 (en) |
KR (1) | KR102598466B1 (en) |
CN (1) | CN110637022B (en) |
AU (1) | AU2018257778B2 (en) |
BR (1) | BR112019022307A2 (en) |
CA (1) | CA3059449A1 (en) |
DK (1) | DK3615545T3 (en) |
EA (1) | EA039181B1 (en) |
ES (1) | ES2901875T3 (en) |
IL (1) | IL269900B (en) |
MX (1) | MX2019012759A (en) |
NZ (1) | NZ757442A (en) |
PH (1) | PH12019502376A1 (en) |
PL (1) | PL3615545T3 (en) |
SG (1) | SG11201909478UA (en) |
TW (1) | TWI778052B (en) |
WO (1) | WO2018200425A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022505183A (en) * | 2018-10-17 | 2022-01-14 | コクリスタル ファーマ,インコーポレイテッド | Influenza virus replication inhibitor combination |
KR20210091753A (en) * | 2018-11-13 | 2021-07-22 | 코크리스탈 파마, 아이엔씨. | Influenza treatment formulation |
JP7484901B2 (en) | 2019-04-26 | 2024-05-16 | 日産化学株式会社 | Method for producing arylsulfonic acid ester compound |
TW202202500A (en) * | 2020-07-10 | 2022-01-16 | 大陸商四川海思科製藥有限公司 | Pb2 inhibitor, and preparation method therefor and use thereof |
WO2022109495A1 (en) * | 2020-11-23 | 2022-05-27 | The Regents Of The University Of California | Methods and compositions for linking rna stem loops |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB278965A (en) | 1927-03-24 | 1927-10-20 | Gerhard Haar | Improved agricultural plough |
US4131648A (en) | 1975-01-28 | 1978-12-26 | Alza Corporation | Structured orthoester and orthocarbonate drug delivery devices |
US4180646A (en) | 1975-01-28 | 1979-12-25 | Alza Corporation | Novel orthoester polymers and orthocarbonate polymers |
US4093709A (en) | 1975-01-28 | 1978-06-06 | Alza Corporation | Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates) |
US4079038A (en) | 1976-03-05 | 1978-03-14 | Alza Corporation | Poly(carbonates) |
GB2064336B (en) | 1979-12-06 | 1984-03-14 | Glaxo Group Ltd | Device for dispensing medicaments |
US4304767A (en) | 1980-05-15 | 1981-12-08 | Sri International | Polymers of di- (and higher functionality) ketene acetals and polyols |
US4353656A (en) | 1980-10-14 | 1982-10-12 | Xerox Corporation | Moving coil, multiple energy print hammer system including a closed loop servo |
ATE23272T1 (en) | 1981-07-08 | 1986-11-15 | Draco Ab | POWDER INHALER. |
CH662277A5 (en) | 1982-10-08 | 1987-09-30 | Glaxo Group Ltd | MEDICINE ADMINISTRATOR. |
US4778054A (en) | 1982-10-08 | 1988-10-18 | Glaxo Group Limited | Pack for administering medicaments to patients |
GB2169265B (en) | 1982-10-08 | 1987-08-12 | Glaxo Group Ltd | Pack for medicament |
US4501729A (en) | 1982-12-13 | 1985-02-26 | Research Corporation | Aerosolized amiloride treatment of retained pulmonary secretions |
US4753788A (en) | 1985-01-31 | 1988-06-28 | Vestar Research Inc. | Method for preparing small vesicles using microemulsification |
BE905189A (en) | 1985-07-30 | 1987-01-29 | Glaxo Group Ltd | DEVICE FOR DELIVERING MEDICINES TO PATIENTS. |
US4946931A (en) | 1989-06-14 | 1990-08-07 | Pharmaceutical Delivery Systems, Inc. | Polymers containing carboxy-ortho ester and ortho ester linkages |
WO1991007947A1 (en) | 1989-12-05 | 1991-06-13 | Ramsey Foundation | Neurologic agents for nasal administration to the brain |
GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
US6413536B1 (en) | 1995-06-07 | 2002-07-02 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system and medical or surgical device |
US5968543A (en) | 1996-01-05 | 1999-10-19 | Advanced Polymer Systems, Inc. | Polymers with controlled physical state and bioerodibility |
US6956021B1 (en) | 1998-08-25 | 2005-10-18 | Advanced Inhalation Research, Inc. | Stable spray-dried protein formulations |
JP4859317B2 (en) | 1999-08-06 | 2012-01-25 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | Drug release biodegradable fiber implant |
US7678364B2 (en) | 1999-08-25 | 2010-03-16 | Alkermes, Inc. | Particles for inhalation having sustained release properties |
US6749835B1 (en) | 1999-08-25 | 2004-06-15 | Advanced Inhalation Research, Inc. | Formulation for spray-drying large porous particles |
US7252840B1 (en) | 1999-08-25 | 2007-08-07 | Advanced Inhalation Research, Inc. | Use of simple amino acids to form porous particles |
US6632666B2 (en) | 2000-01-14 | 2003-10-14 | Biolife Solutions, Inc. | Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media |
US6613355B2 (en) | 2000-05-11 | 2003-09-02 | A.P. Pharma, Inc. | Semi-solid delivery vehicle and pharmaceutical compositions |
WO2002013897A2 (en) | 2000-08-14 | 2002-02-21 | Advanced Inhalation Research, Inc. | Inhalation device and method |
AU2002230993B2 (en) | 2000-12-29 | 2006-02-02 | Alkermes, Inc. | Particles for inhalation having sustained release properties |
US6766799B2 (en) | 2001-04-16 | 2004-07-27 | Advanced Inhalation Research, Inc. | Inhalation device |
US6848197B2 (en) | 2001-04-18 | 2005-02-01 | Advanced Inhalation Research, Inc. | Control of process humidity to produce large, porous particles |
KR100894167B1 (en) | 2001-08-14 | 2009-04-22 | 토야마 케미칼 컴퍼니 리미티드 | Novel Virus Proliferation Inhibition/Virucidal method and Novel Pyrazine Nucleotide/Pyrazine Nucleoside Analogue |
US6524606B1 (en) | 2001-11-16 | 2003-02-25 | Ap Pharma, Inc. | Bioerodible polyorthoesters containing amine groups |
CA2465675C (en) | 2001-11-20 | 2008-06-10 | Advanced Inhalation Research, Inc. | Improved particulate compositions for pulmonary delivery |
US7008644B2 (en) | 2002-03-20 | 2006-03-07 | Advanced Inhalation Research, Inc. | Method and apparatus for producing dry particles |
EP1673123A2 (en) | 2003-09-05 | 2006-06-28 | Kurve Technology, Inc. | Integrated nebulizer and particle dispersing chamber for delivery of medicament |
DK2332940T3 (en) | 2004-03-30 | 2013-02-11 | Vertex Pharma | Azaindoles which can be used as inhibitors of JAK and other protein kinases |
TW201412738A (en) | 2006-01-17 | 2014-04-01 | Vertex Pharma | Azaindoles useful as inhibitors of janus kinases |
NZ597059A (en) | 2009-06-17 | 2014-01-31 | Vertex Pharma | Inhibitors of influenza viruses replication |
CA2866381C (en) | 2012-03-13 | 2020-03-24 | Gilead Sciences, Inc. | 2'- substituted carba-nucleoside analogs for antiviral treatment |
RU2019104421A (en) | 2013-11-13 | 2019-04-17 | Вертекс Фармасьютикалз Инкорпорейтед | METHODS OF OBTAINING ANTIBODY VIRUS REPLICATION INHIBITORS |
LT3191489T (en) | 2014-09-08 | 2021-01-25 | Janssen Sciences Ireland Unlimited Company | Pyrrolopyrimidines for use in influenza virus infection |
CN105524067A (en) | 2014-09-28 | 2016-04-27 | 江苏柯菲平医药股份有限公司 | 4-substituted pyrrolo[2,3-d]pyrimidine compound and uses thereof |
FR3039227B1 (en) | 2015-07-22 | 2019-12-27 | Safran Aircraft Engines | AIRCRAFT COMPRISING A CARENE REAR PROPELLER WITH MOBILE SHUTTERS INPUT STATOR |
SG11201804225PA (en) * | 2015-12-09 | 2018-06-28 | Sunshine Lake Pharma Co Ltd | Inhibitors of influenza virus replication, application methods and uses thereof |
WO2017133667A1 (en) | 2016-02-05 | 2017-08-10 | Savira Pharmaceuticals Gmbh | Pyrimidine and pyridine derivatives and use in treatment, amelioration or prevention of influenza thereof |
WO2017133664A1 (en) * | 2016-02-05 | 2017-08-10 | Savira Pharmaceuticals Gmbh | Bicyclic pyridine and pyrimidine derivatives and their use in the treatment, amelioration or prevention of influenza |
WO2017198122A1 (en) * | 2016-05-19 | 2017-11-23 | 四川大学 | Anti-influenza small molecule compound and preparation method and use thereof |
DE102017000989A1 (en) * | 2017-02-03 | 2018-08-09 | Evonik Degussa Gmbh | Process for the preparation of cyclododecanone |
-
2018
- 2018-04-24 AU AU2018257778A patent/AU2018257778B2/en active Active
- 2018-04-24 JP JP2020507515A patent/JP7165721B2/en active Active
- 2018-04-24 BR BR112019022307-0A patent/BR112019022307A2/en unknown
- 2018-04-24 TW TW107113876A patent/TWI778052B/en active
- 2018-04-24 WO PCT/US2018/028986 patent/WO2018200425A1/en unknown
- 2018-04-24 SG SG11201909478U patent/SG11201909478UA/en unknown
- 2018-04-24 DK DK18723298.8T patent/DK3615545T3/en active
- 2018-04-24 MX MX2019012759A patent/MX2019012759A/en unknown
- 2018-04-24 NZ NZ757442A patent/NZ757442A/en unknown
- 2018-04-24 KR KR1020197033668A patent/KR102598466B1/en active IP Right Grant
- 2018-04-24 PL PL18723298T patent/PL3615545T3/en unknown
- 2018-04-24 EP EP18723298.8A patent/EP3615545B1/en active Active
- 2018-04-24 CN CN201880030665.3A patent/CN110637022B/en active Active
- 2018-04-24 EA EA201992543A patent/EA039181B1/en unknown
- 2018-04-24 US US16/603,951 patent/US11014941B2/en active Active
- 2018-04-24 ES ES18723298T patent/ES2901875T3/en active Active
- 2018-04-24 CA CA3059449A patent/CA3059449A1/en active Pending
-
2019
- 2019-10-07 IL IL269900A patent/IL269900B/en unknown
- 2019-10-18 PH PH12019502376A patent/PH12019502376A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
ES2901875T3 (en) | 2022-03-24 |
EP3615545A1 (en) | 2020-03-04 |
TWI778052B (en) | 2022-09-21 |
TW201839003A (en) | 2018-11-01 |
PL3615545T3 (en) | 2022-01-10 |
KR102598466B1 (en) | 2023-11-03 |
WO2018200425A1 (en) | 2018-11-01 |
JP7165721B2 (en) | 2022-11-04 |
DK3615545T3 (en) | 2021-11-22 |
IL269900B (en) | 2022-05-01 |
US20200123177A1 (en) | 2020-04-23 |
JP2020517738A (en) | 2020-06-18 |
EA201992543A1 (en) | 2020-03-24 |
CA3059449A1 (en) | 2018-11-01 |
EP3615545B1 (en) | 2021-09-01 |
KR20190140971A (en) | 2019-12-20 |
NZ757442A (en) | 2022-10-28 |
US11014941B2 (en) | 2021-05-25 |
AU2018257778A1 (en) | 2019-10-10 |
PH12019502376A1 (en) | 2020-09-14 |
BR112019022307A2 (en) | 2020-05-26 |
AU2018257778B2 (en) | 2022-02-17 |
MX2019012759A (en) | 2019-12-16 |
EA039181B1 (en) | 2021-12-15 |
CN110637022A (en) | 2019-12-31 |
CN110637022B (en) | 2022-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201909478UA (en) | Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication | |
SG11202000325UA (en) | Selective inhibitors of nlrp3 inflammasome | |
SG11201909325RA (en) | 2-amino-quinoline derivatives | |
SG11201908532UA (en) | Macrocyclic compounds as ros1 kinase inhibitors | |
SG11201808003RA (en) | Bromodomain inhibitors | |
SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
SG11201809559UA (en) | Substituted pyridines as inhibitors of dnmt1 | |
SG11201805645QA (en) | Lsd1 inhibitors | |
SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
SG11201908351TA (en) | Indole derivatives as efflux pump inhibitors | |
SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201811209QA (en) | Oral gastroretentive formulations and uses thereof | |
SG11201908788YA (en) | Combinations of chk1- and wee1 - inhibitors | |
SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201806480UA (en) | Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer | |
SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
SG11201906164RA (en) | Bicyclic inhibitors of histone deacetylase | |
SG11201902988UA (en) | Novel hpv16 non hla-restricted t-cell vaccines, compositions and methods of use thereof | |
SG11201901576QA (en) | Dosage regimen for a controlled-release pth compound | |
SG11201908568XA (en) | Therapeutic compounds and methods | |
SG11201908660RA (en) | N-substituted indole derivatives | |
SG11201407337QA (en) | Cyclodextrin complexation methods for formulating peptide proteasome inhibitors |